Inheritance of rare functional GCKR variants and their contribution to triglyceride levels in families

Significant resources have been invested in sequencing studies to investigate the role of rare variants in complex disease etiology. However, the diagnostic interpretation of individual rare variants remains a major challenge, and may require accurate variant functional classification and the collection of large numbers of variant carriers. Utilizing sequence data from 458 individuals with hypertriglyceridemia and 333 controls with normal plasma triglyceride levels, we investigated these issues using GCKR, encoding glucokinase regulatory protein. Eighteen rare non-synonymous GCKR variants identified in these 791 individuals were comprehensively characterized by a range of biochemical and cell biological assays, including a novel high-throughput-screening-based approach capable of measuring all variant proteins simultaneously. Functionally deleterious variants were collectively associated with hypertriglyceridemia, but a range of in silico prediction algorithms showed little consistency between algorithms and poor agreement with functional data. We extended our study by obtaining sequence data on family members; however, functional variants did not co-segregate with triglyceride levels. Therefore, despite evidence for their collective functional and clinical relevance, our results emphasize the low predictive value of rare GCKR variants in individuals and the complex heritability of lipid traits.

[1]  S. Baltrusch,et al.  Glucose-induced dissociation of glucokinase from its regulatory protein in the nucleus of hepatocytes prior to nuclear export. , 2014, Biochimica et biophysica acta.

[2]  Mindy I. Davis,et al.  A Panel of Diverse Assays to Interrogate the Interaction between Glucokinase and Glucokinase Regulatory Protein, Two Vital Proteins in Human Disease , 2014, PloS one.

[3]  R. Wahl,et al.  Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors , 2013, Nature.

[4]  A. Pautsch,et al.  Crystal structure of glucokinase regulatory protein. , 2013, Biochemistry.

[5]  Samuli Ripatti,et al.  From genetic discovery to future personalized health research , 2013, New biotechnology.

[6]  A. Gloyn,et al.  Small molecular glucokinase activators: has another new anti‐diabetic therapeutic lost favour? , 2013, British journal of pharmacology.

[7]  A. Ktorza,et al.  Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans , 2013, British journal of pharmacology.

[8]  Dieter Braun,et al.  Label-Free Microscale Thermophoresis Discriminates Sites and Affinity of Protein–Ligand Binding , 2012, Angewandte Chemie.

[9]  S. Wehrli,et al.  Effects of a glucokinase activator on hepatic intermediary metabolism: study with 13C-isotopomer-based metabolomics. , 2012, The Biochemical journal.

[10]  Adam Kiezun,et al.  Exome sequencing and the genetic basis of complex traits , 2012, Nature Genetics.

[11]  Inês Barroso,et al.  Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes , 2012, Nature Genetics.

[12]  M. McCarthy,et al.  Correlation of rare coding variants in the gene encoding human glucokinase regulatory protein with phenotypic, cellular, and kinetic outcomes. , 2012, The Journal of clinical investigation.

[13]  Yue Shentu,et al.  Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes , 2011, Diabetes Care.

[14]  F. Collins,et al.  Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk , 2011, Diabetologia.

[15]  V. Salomaa,et al.  An Increased Burden of Common and Rare Lipid-Associated Risk Alleles Contributes to the Phenotypic Spectrum of Hypertriglyceridemia , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[16]  A. Gonzalez-Perez,et al.  Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. , 2011, American journal of human genetics.

[17]  S. Ellard,et al.  Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations. , 2010, Genetic testing and molecular biomarkers.

[18]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[19]  V. Salomaa,et al.  Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia , 2010, Nature Genetics.

[20]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[21]  Nicola L. Beer,et al.  The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver , 2009, Human molecular genetics.

[22]  F. Matschinsky,et al.  Assessing the potential of glucokinase activators in diabetes therapy , 2009, Nature Reviews Drug Discovery.

[23]  M. Rieder,et al.  Common Missense Variant in the Glucokinase Regulatory Protein Gene Is Associated With Increased Plasma Triglyceride and C-Reactive Protein but Lower Fasting Glucose Concentrations , 2008, Diabetes.

[24]  Marcia M. Nizzari,et al.  Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels , 2007, Science.

[25]  S. Baltrusch,et al.  Interaction of glucokinase with the liver regulatory protein is conferred by leucine-asparagine motifs of the enzyme. , 2005, Diabetes.

[26]  Peter J. Coassin,et al.  Piezo- and solenoid valve-based liquid dispensing for miniaturized assays. , 2005, Assay and drug development technologies.

[27]  A. Hattersley,et al.  Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. , 2003, Diabetes.

[28]  Klaus Brusgaard,et al.  The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. , 2002, Diabetes.

[29]  S. Henikoff,et al.  Predicting deleterious amino acid substitutions. , 2001, Genome research.

[30]  M. Permutt,et al.  Variable effects of maturity-onset-diabetes-of-youth (MODY)-associated glucokinase mutations on substrate interactions and stability of the enzyme. , 1995, The Biochemical journal.

[31]  S. Hunt,et al.  Genetic heritability and common environmental components of resting and stressed blood pressures, lipids, and body mass index in Utah pedigrees and twins. , 1989, American journal of epidemiology.

[32]  M. Mueckler.  Implications for Glucose Homeostasis and Diabetes , 1990 .